Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 294,403,712
  • Shares Outstanding, K 5,610,896
  • Annual Sales, $ 81,288 M
  • Annual Income, $ 21,980 M
  • 60-Month Beta 0.76
  • Price/Sales 3.50
  • Price/Cash Flow 9.34
  • Price/Book 3.46
Trade PFE with:

Options Overview Details

View History
  • Implied Volatility 30.70% ( +0.80%)
  • Historical Volatility 27.13%
  • IV Percentile 56%
  • IV Rank 58.62%
  • IV High 40.61% on 02/07/22
  • IV Low 16.65% on 06/11/21
  • Put/Call Vol Ratio 1.10
  • Today's Volume 56,857
  • Volume Avg (30-Day) 41,294
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 1,970,718
  • Open Int (30-Day) 1,919,333

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 2.02
  • Number of Estimates 4
  • High Estimate 2.59
  • Low Estimate 1.54
  • Prior Year 1.07
  • Growth Rate Est. (year over year) +88.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.12 +11.35%
on 04/25/22
52.70 -0.44%
on 05/20/22
+2.72 (+5.47%)
since 04/20/22
3-Month
45.40 +15.57%
on 02/24/22
56.32 -6.84%
on 04/11/22
+3.94 (+8.12%)
since 02/18/22
52-Week
38.47 +36.37%
on 06/08/21
61.71 -14.97%
on 12/20/21
+12.35 (+30.78%)
since 05/20/21

Most Recent Stories

More News
Short Straddle Screener Results For March 1st

A short straddle is an advanced options strategy used when a trader is seeking to profit from an underlying stock trading in a narrow range. To execute the strategy, a trader would sell a call and a put...

PFE : 52.47 (+3.59%)
GE : 75.25 (-0.65%)
CSCO : 42.94 (+2.92%)
ABBV : 151.01 (-0.47%)
FDX : 200.90 (+0.93%)
Have $2,000? 2 Market Crash-Ready Stocks to Buy

These stocks have great long-term prospects.

VRTX : 258.59 (+1.23%)
CRSP : 56.34 (-0.27%)
PFE : 52.47 (+3.59%)
BHVN : 142.03 (+0.69%)
Final-hour rally yanks Wall Street from maw of bear market

NEW YORK (AP) — Wall Street rumbled to the edge of a Friday after another drop for stocks briefly sent the S&P 500 more than 20% below its peak set early this year.

$SPX : 3,901.36 (+0.01%)
$DOWI : 31,261.90 (+0.03%)
$IUXX : 11,835.62 (-0.34%)
CSCO : 42.94 (+2.92%)
PFE : 52.47 (+3.59%)
WMT : 119.20 (+0.11%)
TGT : 155.36 (+1.26%)
TSLA : 663.90 (-6.42%)
Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding

Different dynamics are at work for these vaccine stocks.

PFE : 52.47 (+3.59%)
MRNA : 136.25 (-4.97%)
NVAX : 53.42 (-8.57%)
Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide

FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).

AZN : 66.21 (+2.59%)
PFE : 52.47 (+3.59%)
LLY : 298.85 (+4.39%)
ABBV : 151.01 (-0.47%)
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

PFE : 52.47 (+3.59%)
ALKS : 30.00 (+1.76%)
ENTA : 41.87 (-4.86%)
ABEO : 0.1560 (-7.96%)
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

Sector ETF report for FHLC

FHLC : 61.14 (+1.12%)
UNH : 485.73 (+1.50%)
JNJ : 176.98 (+1.75%)
PFE : 52.47 (+3.59%)
XLV : 129.78 (+1.22%)
VHT : 237.47 (+1.21%)
Why Pfizer Looks Better Than Moderna as a Long-Term Buy

In a post-COVID world, there are fewer question marks about Pfizer than there are about Moderna.

MRNA : 136.25 (-4.97%)
PFE : 52.47 (+3.59%)
BHVN : 142.03 (+0.69%)
Moderna (MRNA) Stock Rises 4%: What's Behind the Upside?

Moderna (MRNA) stock rises more than 4% on May 17. The COVID-19 vaccine-maker attracts investors on the back of a promising update from one of its competitors.

JNJ : 176.98 (+1.75%)
PFE : 52.47 (+3.59%)
MRNA : 136.25 (-4.97%)
BNTX : 163.00 (-2.90%)
Pfizer (PFE) Gets EUA for Use of Comirnaty Booster in Children

Pfizer (PFE) and partner BioNTech gets authorization for emergency use of booster dose of its COVID-19 vaccine, Comirnaty, in children aged between 5 years and 11 years.

PFE : 52.47 (+3.59%)
MRK : 93.55 (+1.59%)
MRNA : 136.25 (-4.97%)
BNTX : 163.00 (-2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 54.64
2nd Resistance Point 53.67
1st Resistance Point 53.07
Last Price 52.47
1st Support Level 51.50
2nd Support Level 50.53
3rd Support Level 49.93

See More

52-Week High 61.71
Fibonacci 61.8% 52.83
Last Price 52.47
Fibonacci 50% 50.09
Fibonacci 38.2% 47.35
52-Week Low 38.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar